How to Sell a Medical Practice in 2026: Multiples, PE Consolidators, and the Stark Law / Anti-Kickback Reality

Selling a medical practice in 2026 is structurally different from selling almost any other professional services business. The buyer pool is concentrated and specialty-segmented. The deal mechanics are uniquely sensitive to physician retention, insurance contract transfer, and credentialing timelines. And the entire transaction sits on top of a regulatory framework — Stark Law, the Anti-Kickback Statute, state corporate practice of medicine doctrines — that can transform a routine deal into personal civil or criminal exposure if structured carelessly.

This guide is for physician-owners with $1M-$10M in normalized EBITDA who are 12-36 months from exit. Whether you operate a solo primary care practice, a multi-physician specialty group, an ambulatory surgery center, or a multi-site specialty platform, the realities below apply. We’ll walk through realistic multiples by specialty, the PE consolidator landscape, the regulatory and credentialing workstreams, and the preparation steps that materially improve outcomes.

The framework draws on direct work with 76+ active U.S. lower middle market buyers, including specialty PE consolidators, hospital health systems, payor-owned platforms (Optum), and physician-led MSO (management services organization) platforms. We’re a buy-side partner. The buyers pay us when a deal closes — not you. That includes the largest healthcare consolidators (Optum/UnitedHealth, USPI/Tenet, HCA Healthcare), specialty platforms (Schweiger Dermatology, ADCS, EyeCare Partners, HOPCo, US Acute Care Solutions, US Anesthesia Partners), and PE platforms backing emerging specialty consolidators. The goal of this article isn’t to convince you to sell — it’s to give you an honest read on what selling a physician practice actually looks like in 2026.

One realistic note before you start. If a broker has told you your practice is worth a flat “10x EBITDA because healthcare is hot,” pressure-test the number against your specialty. Solo internal medicine trades 4-6x; multi-site dermatology trades 12-15x; ASCs trade 7-11x; cardiology platforms trade 8-12x. Anchoring on a headline cross-specialty number costs sellers $1-5M of after-tax proceeds in the typical deal.

“The mistake most physician-owners make is treating their practice like any other professional services business. Stark Law, Anti-Kickback, fair-market-value documentation, and credentialing transfer make medical practice M&A uniquely high-stakes — and the right answer is a buy-side partner who already knew the regulated buyers, not a broker selling them a process.”

Key Takeaways

• Realistic multiples: solo primary care 4-6x EBITDA; multi-physician primary care 6-9x; specialty solo 6-9x; specialty multi-physician 8-12x; multi-site specialty platforms 12-15x.
• Buyer pool: Optum (UnitedHealth) is the largest physician employer; USPI (Tenet) leads ASC consolidation; specialty platforms (dermatology: ADCS/Schweiger; ophthalmology: EyeCare Partners; orthopedics: HOPCo) lead specialty M&A.
• Stark Law (42 USC 1395nn) and Anti-Kickback (42 USC 1320a-7b) constrain valuation, physician comp post-close, and earn-out structures — all asset values must reflect fair market value with independent appraisal.
• Insurance contract transfer and physician credentialing typically add 90-180 days to the deal timeline; failing to plan creates revenue gaps post-close.
• Most states impose corporate practice of medicine restrictions; consolidators use MSO/PC structures (management services organizations operating under contract with physician-owned PCs) to comply.
• Process timeline: 6-12 months for a multi-physician specialty practice; 9-15 months for multi-site or platform deals due to deeper diligence and physician retention work.

Why medical practices command premium multiples in 2026

Healthcare services have been one of the most actively consolidated sectors in US M&A for the past decade, and the consolidation thesis remains durable through 2026. US healthcare spending continues to grow above general inflation (CMS National Health Expenditure data tracks $4.5T+ in 2023, projected to reach $6.8T by 2030), payors increasingly favor large physician groups for negotiating leverage and value-based care contracts, and the demographic backdrop (aging population, chronic-disease prevalence) creates structural demand growth across most specialties.

Consolidator economics drive the multiples. A national platform like Optum or a specialty consolidator like EyeCare Partners spreads back-office costs (revenue cycle management, payor contracting, compliance, IT, HR, recruiting) across hundreds of locations, captures volume discounts on supplies and pharmaceuticals, negotiates better commercial payor rates as a regional market leader, and can pay competitive physician compensation while retaining 18-25% EBITDA margins. A standalone specialty practice running clean might hit 25-30% margins; the consolidator’s combination of margin retention plus scale-driven cost and reimbursement advantages explains why they pay 10-15x for assets the seller couldn’t buy back at 5x.

Specialty-specific premiums. Procedural and outpatient-friendly specialties trade highest: dermatology (high recurring patient panels, cosmetic upside, ASC-friendly), ophthalmology (cataract surgery volume + ASC integration), orthopedics (sports medicine + ASC + DME), gastroenterology (endoscopy ASC integration), cardiology (high-acuity outpatient procedures), pain management (procedural recurrence), and urology (procedural mix). Primary care, internal medicine, and pediatric practices trade lower (5-8x) unless they have payor contracts (Medicare Advantage capitation, ACO participation) that make them strategically valuable to risk-bearing platforms like Optum or VillageMD.

The medical practice buyer pool in 2026: who actually writes checks

The medical practice buyer pool divides into roughly five archetypes, each with distinct buy-boxes, regulatory comfort, and physician compensation philosophies. Knowing which archetype fits your practice is the highest-leverage positioning decision. Pitching a solo primary care practice to a specialty PE consolidator wastes 4-6 months; pitching a 10-physician dermatology platform to a hospital health system often leaves $5-15M of multiple on the table relative to a dermatology-specific PE consolidator.

Archetype 1: Payor-owned platforms (Optum / UnitedHealth, Humana / CenterWell, Elevance / Carelon). Optum (subsidiary of UnitedHealth Group) is the largest single employer of US physicians, with primary care, specialty, urgent care, surgical, and ambulatory businesses. Humana’s CenterWell focuses on Medicare Advantage primary care. Buy-box: primary care groups with strong Medicare Advantage panels, multi-specialty groups in target metros, ASCs and surgical platforms. Multiples: 8-15x EBITDA depending on segment, often with significant physician compensation continuity.

Archetype 2: Specialty PE consolidators. PE-backed national platforms focused on specific specialties. Dermatology: ADCS (Advanced Dermatology and Cosmetic Surgery, backed by Harvest Partners), Schweiger Dermatology (LCAP), Pinnacle Dermatology, US Dermatology Partners. Ophthalmology: EyeCare Partners (Partners Group), Spectrum Vision Partners, Unifeye Vision Partners. Orthopedics: HOPCo (Healthcare Outcomes Performance Co, backed by Audax), OrthoOne, US Orthopaedic Partners. Cardiology: Cardiovascular Associates of America (Webster), US Heart and Vascular. Anesthesia/perioperative: US Anesthesia Partners (Welsh Carson, GTCR, Berkshire Partners). Multiples: 10-15x EBITDA for specialty groups, 12-18x for platform-quality multi-site groups.

Archetype 3: ASC consolidators. USPI (United Surgical Partners International, owned by Tenet Healthcare) is the largest US ASC operator with 480+ centers. SCA Health (now part of Optum) is the second-largest. AmSurg (originally divested by Envision, now part of Surgery Partners) operates a national network. Multiples for standalone ASCs: 7-11x EBITDA, with premium for high-acuity procedural mix (orthopedic, cardiology, GI), strong physician partnerships, and out-of-network revenue stability. ASC-attached physician practice deals often run 10-13x blended.

Archetype 4: Hospital health systems and academic medical centers. Major systems (HCA Healthcare, Ascension, Trinity Health, CommonSpirit, AdventHealth, Northwell, NYU Langone, Cleveland Clinic, Mayo Clinic) and regional systems acquire physician practices for both clinical integration and referral capture. Multiples: 4-9x EBITDA typically — below PE consolidators but with employment certainty, hospital privileges, and academic affiliation benefits. Hospital deals often emphasize physician employment security over headline price.

Archetype 5: Physician-led MSO and partnership models. Physician-controlled MSO platforms (US Acute Care Solutions, Vituity, Sound Physicians) and partnership-style platforms where physicians retain meaningful equity and governance roles. Multiples: 8-12x EBITDA, often with substantial rollover equity (20-40%). The trade-off relative to corporate consolidators: lower headline price but more physician autonomy, partnership-track culture, and rollover-equity upside if the platform sells in 4-7 years.

Buyer archetype	Typical multiple	Specialty fit	Distinguishing feature
Payor-owned (Optum, CenterWell, Carelon)	8-15x EBITDA	Primary care w/ MA, multi-specialty, ASC	Largest physician employer; risk-bearing focus
Specialty PE consolidators	10-15x EBITDA (12-18x platform)	Derm, ophtho, ortho, GI, cardio, pain, anesthesia	Specialty-specific buy-boxes, MSO/PC structure
ASC consolidators (USPI, SCA, Surgery Partners)	7-11x EBITDA	ASCs and ASC-attached practices	Operational expertise, physician partnership
Hospital health systems	4-9x EBITDA	Most specialties, varies by region	Employment certainty over headline price
Physician-led MSO / partnership	8-12x EBITDA + rollover	Specialty-dependent	Physician autonomy, rollover equity

Buyer type	Cash at close	Rollover equity	Exclusivity	Best fit for
Strategic acquirer	High (40–60%+)	Low (0–10%)	60–90 days	Sellers who want a clean exit; competitor or upstream consolidator
PE platform	Medium (60–80%)	Medium (15–25%)	60–120 days	Sellers willing to hold rollover for the second sale; bigger deals
PE add-on	Higher (70–85%)	Low–Medium (10–20%)	45–90 days	Sellers folding into existing platform; faster process
Search fund / ETA	Medium (50–70%)	High (20–40%)	90–180 days	Legacy-conscious sellers wanting an owner-operator successor
Independent sponsor	Medium (55–75%)	Medium (15–30%)	60–120 days	Sellers OK with deal-by-deal capital and longer financing closes

Realistic multiples by specialty: what the data shows

Medical practice multiples vary more by specialty than almost any other professional services category. The drivers are buyer-pool depth (active PE consolidators in your specialty), procedural mix (procedural specialties trade higher than cognitive/E&M-focused), payor mix (commercial-heavy practices trade higher than Medicaid-heavy), and recurring patient relationships (chronic care management commands premium).

Primary care, internal medicine, family medicine, pediatrics: 4-9x EBITDA. Solo or small group practices: 4-6x. Multi-physician with strong commercial mix: 6-8x. Multi-physician with significant Medicare Advantage panel and risk-bearing capability: 8-12x (Optum, ChenMed, Oak Street, VillageMD active). The biggest swing factor is risk-bearing capability — primary care groups that can take on Medicare Advantage capitation or Medicare Shared Savings Program (MSSP) risk command meaningfully higher multiples than fee-for-service-only groups.

Dermatology: 8-15x EBITDA, with multi-site platforms reaching 18x+. One of the most aggressively consolidated specialties since 2015. Buyer pool: ADCS, Schweiger, Pinnacle Dermatology, US Dermatology Partners, plus regional PE-backed platforms. Multiples lift with: Mohs surgery integration, cosmetic/aesthetic revenue mix, multi-site density, recurring patient panels, dermatopathology integration. Solo derm trades 7-9x; 3-5 provider groups 9-12x; multi-site platforms with $5M+ EBITDA 12-18x.

Ophthalmology: 7-13x EBITDA, with ASC-integrated platforms reaching 15x+. Buyer pool: EyeCare Partners, Spectrum Vision Partners, Unifeye Vision Partners, ASC consolidators interested in ophthalmology surgical centers. Multiples lift with: cataract surgery volume, ASC integration, premium IOL adoption, retinal subspecialty integration, optical retail integration. Solo ophthalmology trades 6-8x; multi-physician with ASC 10-13x; multi-site platforms 13-18x.

Orthopedics, sports medicine: 8-13x EBITDA. Buyer pool: HOPCo, OrthoOne, US Orthopaedic Partners, Town Center Orthopaedic Associates, regional PE platforms. Multiples lift with: ASC integration, DME (durable medical equipment) ancillary, MRI/imaging integration, sports medicine subspecialty, physical therapy integration. Solo ortho trades 6-8x; multi-physician with ASC 10-13x; multi-site platforms 13-16x.

Gastroenterology: 8-13x EBITDA, with endoscopy ASC-integrated platforms higher. Buyer pool: GI Alliance (Apollo / Webster), United Digestive (Frazier Healthcare), Gastro Health (Audax), One GI. Multiples lift with: ASC endoscopy integration, anesthesia partnership, pathology integration, hepatology/IBD subspecialty. Solo GI trades 6-9x; multi-physician with endoscopy ASC 10-13x; multi-site platforms 13-16x.

Cardiology: 7-12x EBITDA. Buyer pool: Cardiovascular Associates of America (Webster), US Heart and Vascular, regional PE-backed platforms. Multiples lift with: cath lab and EP lab integration, cardiac imaging integration, structural heart program, vascular surgery subspecialty. Solo cardiology trades 5-7x; multi-physician with cath lab 9-12x; multi-site platforms 12-15x.

Other specialty patterns. Pain management: 6-10x EBITDA (procedural mix, drug screening compliance issues weigh on margins). Urology: 7-11x EBITDA (lithotripsy, in-office procedures, men’s health subspecialty drive premium). ENT: 6-10x EBITDA. OB/GYN: 5-8x EBITDA (lower consolidator interest historically, picking up with women’s health platforms). Psychiatry/behavioral health: 8-12x EBITDA (telehealth integration, ARTreatment, Refresh Mental Health, Octave active). Anesthesiology and pathology: 8-12x EBITDA (national consolidators dominant).

Specialty	Typical multiple	Active consolidators	Multiple drivers
Primary care (FFS)	4-7x EBITDA	Hospital systems, regional PE	Commercial mix, panel size
Primary care (MA / risk-bearing)	8-12x EBITDA	Optum, CenterWell, ChenMed, Oak Street, VillageMD	MA panel size, risk-contract maturity
Dermatology	8-15x (18x+ platform)	ADCS, Schweiger, Pinnacle, US Derm Partners	Mohs, cosmetic, multi-site density
Ophthalmology	7-13x (15x+ ASC platform)	EyeCare Partners, Spectrum, Unifeye	ASC, cataract volume, premium IOL
Orthopedics / sports medicine	8-13x	HOPCo, OrthoOne, US Ortho Partners	ASC, DME, imaging, PT
Gastroenterology	8-13x	GI Alliance, United Digestive, Gastro Health, One GI	Endoscopy ASC, anesthesia, pathology
Cardiology	7-12x	CVAUSA, US Heart and Vascular	Cath lab, EP lab, structural heart
ASCs (standalone)	7-11x	USPI, SCA, Surgery Partners, AmSurg	Procedural mix, physician partnerships

Stark Law and Anti-Kickback: the regulatory backbone of every deal

Every physician-practice transaction is structured to comply with two federal laws that constrain valuation, physician compensation, and deal structure: the Stark Law (Physician Self-Referral Law, 42 USC 1395nn) and the Anti-Kickback Statute (42 USC 1320a-7b). These laws are not optional. Stark imposes strict liability for prohibited referrals; AKS imposes criminal penalties for knowing violations. Both apply when the practice bills Medicare or Medicaid, which covers essentially every US medical practice. Get the structure wrong and you create personal civil liability (Stark) or criminal exposure (AKS) for the seller, the buyer, and the deal advisors.

The fair market value (FMV) requirement at the heart of every deal. Both Stark and AKS require that asset purchases, physician compensation arrangements, and consulting/non-compete agreements be at fair market value, commercially reasonable, and not determined in a manner that takes into account the volume or value of referrals. In practice, this means: (1) the practice purchase price must be supported by an independent FMV appraisal; (2) post-close physician compensation must be based on personal productivity, not referral generation to designated health services (DHS) like imaging, lab, DME; (3) consulting agreements with selling physicians must reflect actual hours and FMV rates; (4) non-compete consideration must be reasonable.

Why “goodwill” valuation matters more in healthcare than elsewhere. In most M&A, goodwill represents the going-concern value of the business above tangible assets. In healthcare, regulators look skeptically at large goodwill payments to physicians because excess goodwill can be characterized as disguised payment for future referrals (an AKS concern). Independent FMV appraisals from credentialed healthcare valuation firms (HealthCare Appraisers, VMG Health, Pinnacle Healthcare Consulting, Stout) are essential evidence of arms-length pricing.

Physician compensation structures post-close. The buyer’s post-close physician compensation arrangement must comply with Stark’s “personally performed services” standard and AKS safe harbors. Most consolidators use either (1) wRVU-based compensation with FMV per-wRVU rates, (2) percentage-of-collections from the physician’s personally performed services, or (3) base salary plus performance bonuses tied to quality metrics not linked to DHS referrals. Compensation that varies with the volume of referrals to ancillary services (imaging, labs, ASCs the physician owns) is a Stark violation absent a specific exception.

Earn-outs and consulting agreements. Earn-outs in physician practice deals are constrained: they cannot be tied to referral volume or value, and they must be commercially reasonable. Common structures: earn-outs tied to overall practice EBITDA performance (acceptable), earn-outs tied to physician retention milestones (acceptable), earn-outs tied to specific referral volumes (Stark/AKS violation). Consulting agreements with selling physicians post-close must reflect actual hours, FMV rates, and non-overlap with employed-physician duties. The OIG has issued multiple advisory opinions and enforcement actions on these structures — current Stark/AKS-experienced healthcare counsel is mandatory, not optional.

Corporate practice of medicine and MSO/PC structures. Most US states impose some form of corporate practice of medicine doctrine, restricting non-physician ownership of physician practices. Consolidators (PE platforms, payor-owned platforms, hospital systems) typically operate through MSO/PC structures: the management services organization (MSO) is owned by the consolidator; the professional corporation (PC) is owned by physicians; the MSO provides management services to the PC under a long-term agreement at FMV rates. The structure is well-established but requires careful state-by-state legal review.

Insurance contract transfer and physician credentialing

Physician practices generate revenue through insurance contracts (Medicare, Medicaid, commercial payors) tied to specific provider entities and individual physician credentials. At sale, both the entity-level contracts and the individual physician credentials must transfer or be re-issued. This workstream typically takes 90-180 days and runs in parallel with other diligence. Failing to plan creates revenue gaps post-close where the practice can’t bill or collects at out-of-network rates.

Medicare and Medicaid enrollment. Medicare provider enrollment runs through PECOS (Provider Enrollment, Chain, and Ownership System). On a change of ownership (CHOW), the new owner typically must apply for new Medicare enrollment using Form CMS-855A (institutional provider) or CMS-855I (individual physician) and CMS-855B (group). Two structures: (1) full new enrollment, which can take 90-150 days and creates a billing gap during the lag, or (2) CHOW with assumption of the existing provider number, which preserves billing continuity but requires CMS approval. Medicaid varies by state but follows similar patterns.

Commercial payor contracts. Commercial payor contracts (UnitedHealthcare, Anthem, Aetna, Cigna, Humana, regional Blues, employer plans) often have change-of-control or assignment clauses requiring payor consent for transfer. Some contracts terminate on change of ownership; others transfer with notice; others require the new entity to re-apply. Plan to map every payor contract during diligence and start re-credentialing or transfer notice 90-120 days before close. Consolidators with existing payor relationships often move faster, but the workstream still requires attention.

Individual physician credentialing. Individual physicians must be credentialed with each payor and at each hospital where they have privileges. On a change of practice ownership, individual credentials typically transfer with the physician but must be updated to reflect the new entity. Hospital privileges require notification but typically continue during transition. Re-credentialing (rather than transfer) can take 90-180 days per payor; physicians billing under the wrong entity during the gap may have claims denied retroactively.

Common credentialing failure patterns. Practice closes before all payor contracts are transferred — results in 30-60 days of denied claims that must be appealed individually. Individual physicians’ credentials lag the entity transfer — physicians can’t see in-network patients during the gap. Hospital privileges expire mid-transition — physicians lose admitting rights at affiliated hospitals. State licensing renewals get missed during distraction of close. Each of these has caused 5-15% revenue impact in the first quarter post-close, which buyers either negotiate around in working capital or claw back in earn-outs.

What buyers actually look for in medical practice diligence

Medical practice diligence is more comprehensive and regulated than typical professional services M&A. Expect a $75-150K Quality of Earnings engagement, a healthcare-specific compliance review, an independent FMV appraisal, a clinical operations review, and a payor contract analysis. The total diligence runway is typically 90-150 days for a multi-physician practice and 120-180 days for multi-site or platform deals.

Financial diligence focus areas. (1) Revenue mix by payor (commercial vs Medicare vs Medicaid vs self-pay) — commercial-heavy practices command premium. (2) Procedural vs E&M revenue split. (3) Ancillary revenue (imaging, lab, ASC, infusion, pathology) — with Stark/AKS scrutiny. (4) Add-back legitimacy — physician personal expenses, family on payroll, owner perks. (5) Working capital — AR aging by payor, denial rates, days in AR. (6) Physician productivity by wRVU and collections.

Compliance diligence focus areas. (1) Stark Law compliance: physician compensation structures, ancillary service ownership, group practice qualification. (2) AKS compliance: referral relationships, marketing arrangements, manufacturer payments (Open Payments / Sunshine Act database). (3) HIPAA compliance: business associate agreements, security risk assessment, breach history. (4) Coding and billing compliance: audit history, OIG exclusion checks, RAC/MAC findings, false claims risk. (5) Professional liability: claims history, current insurance, tail coverage planning. (6) State licensing: physician licenses, DEA registrations, state medical board complaint history.

Clinical and operational diligence. Buyer’s clinical team reviews: case mix and complexity, EHR (Epic, Cerner, Athena, eClinicalWorks, Allscripts) capabilities and adoption, quality metrics (HEDIS, MIPS, ACO performance), patient satisfaction data, physician training and board certifications, staff credentials (NPs, PAs, MAs, RNs), facility compliance (OSHA, CLIA for in-office labs, radiation safety).

Common diligence issues that re-price or kill medical practice deals. Stark/AKS structural issues (physician comp tied to ancillary referrals, ASC ownership without proper safe harbor compliance, pharmaceutical or device manufacturer payments without proper structure) — these can be deal-killers, not just price reducers. HIPAA breach history without proper notification. Coding patterns suggesting upcoding or unbundling. Open OIG, DOJ, or state Medicaid Fraud Control Unit investigations. Physician compensation arrangements that don’t qualify for a Stark exception. Unfavorable payor contracts with change-of-control termination. Pending malpractice claims with reserve adequacy questions.

Preparing a medical practice for sale: the 18-24 month playbook

Physician-owners who get the best outcomes start prepping 18-24 months before going to market. Healthcare diligence is rigorous enough that you can’t fix Stark/AKS structural issues, financial reporting cleanup, or physician retention in 90 days. Each fix increases the multiple, widens the buyer pool, and reduces re-trade risk during diligence. Skipping prep doesn’t mean a faster exit — it usually means a worse one with higher legal-exposure tail.

Months 24-18: financial cleanup, compliance audit, and KPI baselines. Move to monthly closes within 15 days. Engage a healthcare-experienced CPA for clean annual statements. Run a Stark/AKS compliance audit with experienced healthcare counsel; identify and remediate any structural issues (physician comp tied to referrals, ancillary ownership issues, marketing arrangements). Establish wRVU productivity per physician, collections per wRVU, payor mix, denial rates, days in AR baselines.

Months 18-12: physician retention and team strengthening. Identify which 1-3 physicians are critical to retention. Have private conversations about long-term plans and what would keep them through transition. Ensure physician employment agreements, non-competes, and call coverage agreements are clean and assignable. If you have non-physician owners (rare but exists in some states / structures), document the ownership cleanly. Strengthen practice management roles (administrator, billing manager, compliance officer).

Months 12-6: payor contract review and credentialing audit. Inventory every payor contract; identify change-of-control and assignment clauses. Initiate conversations with major payors about expected transfer process. Audit individual physician credentialing status with each payor and hospital. Ensure DEA registrations and state licenses are current and renewals are not pending. Review professional liability tail coverage requirements.

Months 6-0: prepare the diligence package. Compile 36 months of financial statements, tax returns, payor contracts, physician employment agreements, compliance documentation. Document add-backs with line-item explanations. Compile staff roster with credentials, comp, employment status. Pull HIPAA risk assessment, breach history, business associate agreements. Compile coding audit results, OIG exclusion checks. State medical board, DEA, and state agency status reports. Real estate documentation if relevant.

The realistic medical practice sale timeline

Multi-physician specialty practice sales to PE consolidators typically run 6-12 months from prep-complete to close. Multi-site or platform deals run 9-15 months due to deeper diligence, more complex regulatory workstreams, and physician retention work across multiple locations. Hospital health system deals can run shorter (often 4-7 months) due to existing employer infrastructure but typically involve lower headline multiples.

Months 1-3: positioning and buyer outreach. Build a CIM tailored to the right archetype. For a multi-physician specialty practice, that’s 30-50 pages emphasizing physician productivity, payor mix, ancillary integration, growth runway, and compliance posture. Reach out to 6-12 likely buyers in your specialty. Sign NDAs with serious prospects. Expect 3-6 to engage seriously.

Months 3-5: management meetings and indications of interest. Take 4-6 buyer meetings. Most consolidators send a 3-5 person team (M&A lead, regional operations, clinical leader, sometimes compliance) for a 1-2 day site visit and operational deep-dive. Receive 2-4 indications of interest with non-binding price ranges. Negotiate to LOI with the best fit on price, structure, and physician integration philosophy.

Months 5-9: LOI, diligence, and physician retention negotiation. Sign LOI with 90-120 day exclusivity. Buyer’s QoE and FMV appraisal engages (4-8 weeks). Compliance and clinical diligence runs in parallel. Critical workstreams: physician employment agreement negotiation, payor contract transfer planning, credentialing audit, regulatory transfer (Medicare CHOW, state licensing). MSO/PC structure documentation if applicable.

Months 9-12: close and transition. Final purchase agreement. Working capital target negotiation. Indemnification, escrow, earn-out terms finalized. Medicare CHOW filed. Major commercial payor transfers initiated. Employee notification (typically 24-72 hours pre-close, with retention agreements signed in advance for key physicians). Patient notification per HIPAA and state requirements. Post-close transition: 90-180 days where the selling physician(s) remain employed and active.

Multi-site / platform deal deviations. Multi-site platform deals add 3-6 months. Each site has independent payor contracts, credentialing, state regulatory requirements. Compliance diligence is deeper (more locations = more potential issues). Physician retention is harder (more physicians to align). Medicare CHOW must be filed for each enrolled location. Plan accordingly — multi-site deals that try to compress the timeline create post-close revenue gaps.

Earnout type	How it’s measured	Seller risk	When sellers should accept
Revenue-based	Top-line revenue over 12-24 months	Lower	Default seller preference; harder for buyer to manipulate than EBITDA
EBITDA-based	Adjusted EBITDA over the earnout period	High	Avoid if possible; buyer can manipulate via overhead allocations
Customer retention	% of named customers still buying at month 12, 24	Medium	Reasonable for sellers staying on through transition
Milestone-based	Specific deliverables (license transfer, geographic expansion, etc.)	Lower	Seller has control over the deliverable

Tax planning for medical practice exits

Medical practice sales are typically structured as asset sales, but the structure can vary depending on regulatory considerations and physician ownership status. Asset sales preserve buyer protection from successor liability (malpractice, billing audit findings, employment claims) and provide depreciation step-up. Stock sales are sometimes used in MSO/PC structures or where corporate practice doctrines complicate asset transfers. Each structure has different tax outcomes.

Typical asset allocation in a medical practice sale. Tangible assets (equipment, furniture, supplies): often $200K-$2M depending on specialty (ASCs, imaging, surgical platforms have substantial equipment). Goodwill and intangibles (practice name, patient relationships, going-concern value): typically the bulk of price, capital gains treatment. Non-compete: ordinary income to seller, deductible to buyer. Consulting/transition agreements: ordinary income spread over the consulting term. Real estate (if included): separate treatment.

Why allocation negotiation matters. Buyer pushes value toward equipment (immediate depreciation) and consulting (current expense). Seller pushes toward goodwill (capital gains). The IRS requires reasonable allocation under Form 8594, and FMV-supported documentation is essential in healthcare deals (also required for Stark/AKS compliance). A skilled tax attorney working alongside healthcare-experienced FMV appraisers can shift $200K-$2M of after-tax proceeds in the seller’s favor through allocation negotiation.

QSBS for medical practices: rarely applicable but check. Section 1202 QSBS provides up to $10M of capital gains exclusion (or 10x basis) for stock-sale transactions in qualified C-corp businesses meeting holding period and asset tests. Medical practices are sometimes structured as C-corps, particularly in states with corporate practice flexibility. If your practice has been a C-corp for 5+ years and you’re considering a stock sale, talk to a tax attorney 12+ months before closing. For LLCs, S-corps, and PCs taxed as S, QSBS doesn’t apply.

Rollover equity: often a large portion of medical practice deals. PE consolidators typically offer rollover equity at 20-40% of total consideration. Properly structured (typically through partnership-tax-treated MSO entities), the rollover portion is tax-deferred at close. The seller participates in the consolidator’s subsequent value creation; if the consolidator sells in 4-7 years at higher multiples, rollover equity can produce 1.5-3x return on the rolled portion. The trade-off is illiquidity and dependence on the consolidator’s execution. For most large medical practice deals, rollover is a meaningful component of total economics, not an afterthought.

Common medical practice seller mistakes (and how to avoid them)

Mistake 1: anchoring on the wrong specialty’s multiples. Reading articles about dermatology platforms selling at 15x and assuming the same applies to your solo internal medicine practice. The buyer pool, the consolidator economics, and the procedural mix are all different. Anchor on your actual specialty’s data.

Mistake 2: structuring physician compensation in violation of Stark. Compensating physicians based on ancillary service referrals (in-office imaging, lab, infusion) without proper Stark exception qualification creates strict-liability exposure for both seller and buyer. This is the #1 deal-killer in medical practice M&A. Get Stark/AKS-experienced counsel involved 12-18 months before sale to identify and remediate any compensation structures that don’t qualify for an exception.

Mistake 3: ignoring credentialing and payor contract transfer timelines. Sellers focused on financial close often forget that Medicare CHOW, commercial payor contract transfer, and individual physician credentialing typically take 90-180 days. Failing to start at LOI signing creates 30-90 days of revenue gaps post-close where the practice can’t bill in-network. Build the credentialing checklist into your LOI workplan.

Mistake 4: under-investing in compliance documentation. Healthcare diligence is uniquely focused on compliance: HIPAA risk assessments, business associate agreements, OIG exclusion checks, coding audits, Stark/AKS analysis. Practices that show up to diligence without organized compliance documentation either get re-priced (typically 5-15% reduction) or have deals fall through. $25-50K in pre-sale compliance audit work returns 10-30x at exit.

Mistake 5: secrecy with key physicians. Physician partners or key associates who find out about the sale from outside sources (broker leaks, attorney chatter, banker chatter) often refuse to sign retention agreements or actively oppose the deal. Better pattern: tell key physicians 6-12 months before close that you’re exploring options, that their roles will be protected, and that you’ll advocate for retention compensation they’ll benefit from. In partnership structures, all partners typically must align before any deal can move forward.

Mistake 6: running a generic broker auction. Healthcare M&A is concentrated enough that targeted outreach to the 6-10 buyers most likely to fit your specialty typically beats broad auction marketing. Auctions can also damage relationships with consolidators who feel commodified, and the buyer pool talks. A buy-side intermediary who already knows the specialty consolidators personally usually beats a broker running a process.

How to position for the right medical practice buyer archetype

The biggest single positioning decision is which buyer archetype to target. Each archetype reads CIMs differently, asks different diligence questions, and structures deals differently. A CIM written for a specialty PE consolidator (emphasizing growth runway, multi-site potential, ancillary integration, rollover equity) reads completely differently than one for a hospital health system (emphasizing clinical integration, referral network, employment terms).

Position for specialty PE consolidators when: You operate a multi-physician specialty practice in a target metro, your financial reporting is institutional-grade, your physician retention picture is strong, your ancillary integration (ASC, imaging, lab) is clean from a Stark/AKS perspective, and you’re willing to roll meaningful equity. Emphasize: scale potential, growth runway, clinical quality, capacity to absorb central-office support, willingness to participate in long-term value creation.

Position for payor-owned platforms (Optum, CenterWell) when: You operate a primary care or multi-specialty practice with strong Medicare Advantage panels or risk-bearing capability. Emphasize: panel size, MA penetration, MSSP/ACO participation, quality metric performance, capacity to take on additional risk-bearing arrangements. Optum-style buyers often pay above pure-EBITDA multiples for risk-bearing primary care because the patient panel is the asset.

Position for ASC consolidators when: You operate an ASC or have ASC integration with a procedural specialty (orthopedics, GI, ophthalmology, pain). Emphasize: procedural mix, case volume per OR, physician partner stability, payor contracts, out-of-network revenue durability where relevant. ASC consolidators (USPI, Surgery Partners, SCA) have well-developed buy-boxes and move quickly when fit is clear.

Position for hospital health systems when: Your practice has strong referral relationships with a specific health system, you value employment certainty over headline price, you’re in a market where the hospital system is a major buyer, or you have specialty subspecialty alignment (academic affiliation, fellowship training programs, complex procedural work). Emphasize: clinical integration potential, referral capture, regional fit, willingness to accept hospital-employed model.

Position for physician-led MSO and partnership models when: Physician autonomy and partnership culture matter more than maximum headline price; you have strong physician-leader successors who would benefit from continued ownership stake; you’re willing to roll substantial equity (20-40%). Physician-led platforms typically pay slightly less headline but offer more autonomy and rollover-equity upside if the platform sells in 4-7 years.

Cross-reference your specialty against our broader buyer demand framework. The 2026 LMM Buyer Demand Report documents which sectors have the deepest LMM PE buyer pools. Healthcare specialties dominate the top 10 by buyer activity. The challenge in medical M&A is matching your specific specialty to the specific consolidators with active buy-boxes — the buyer pool exists, but it’s segmented.

Conclusion

Selling a medical practice in 2026 is a real, active market — arguably the deepest professional-services M&A market in the US. But the buyer pool is specialty-segmented, the regulatory framework (Stark, AKS, corporate practice doctrine, payor contract transfer) is uniquely consequential, and the credentialing and CHOW timelines force precise project management. Owners who succeed are the ones who anchor on their specialty’s actual multiples (not cross-specialty headlines), match to the right buyer archetype (specialty PE vs payor vs ASC vs hospital vs physician-led MSO), invest 18-24 months in financial reporting, compliance posture, and physician retention, plan the regulatory transfer and credentialing workstreams from LOI, and negotiate the rollover equity terms with full information. The owners who do this work see 30-50% better after-tax outcomes than the ones who go to market unprepared. And if you want to talk to someone who knows the specialty consolidators personally instead of running an auction, we’re a buy-side partner — the buyers pay us, not you, no contract required.

Frequently Asked Questions

What is my medical practice actually worth in 2026?

It depends entirely on specialty and structure. Solo primary care: 4-6x EBITDA. Multi-physician primary care: 6-9x. Specialty solo: 6-9x. Specialty multi-physician: 8-12x. Multi-site specialty platforms: 12-18x. The biggest swing factors within each category are payor mix (commercial-heavy commands premium), ancillary integration (ASC, imaging, lab), and physician retention strength.

Who are the active PE consolidators in my specialty?

Dermatology: ADCS (Harvest), Schweiger (LCAP), Pinnacle, US Dermatology Partners. Ophthalmology: EyeCare Partners, Spectrum Vision, Unifeye. Orthopedics: HOPCo, OrthoOne, US Orthopaedic Partners. GI: GI Alliance (Apollo), United Digestive (Frazier), Gastro Health (Audax), One GI. Cardiology: CVAUSA (Webster), US Heart and Vascular. Anesthesia: US Anesthesia Partners (Welsh Carson). Pain: Capital Pain Management, regional platforms. Plus payor-owned (Optum, CenterWell) and ASC consolidators (USPI, SCA, Surgery Partners) for cross-specialty.

How does Stark Law affect the deal structure?

Stark requires that asset purchase prices reflect fair market value (FMV) supported by independent appraisal, post-close physician compensation does not vary with referral volume to designated health services (DHS), and ancillary service ownership structures comply with Stark exceptions. Get Stark-experienced healthcare counsel involved 12-18 months pre-sale to identify and remediate structural issues. Stark violations create strict-liability exposure — not optional risk.

What about Anti-Kickback Statute (AKS)?

AKS prohibits knowingly offering or accepting remuneration to induce referrals for items or services payable by federal healthcare programs. In M&A: excess goodwill payments, consulting agreements without genuine services, non-compete consideration without reasonable basis, or physician compensation tied to referrals can all be characterized as disguised kickbacks. Use FMV appraisals from credentialed healthcare valuation firms (HealthCare Appraisers, VMG Health, Pinnacle, Stout) and AKS safe harbors where possible.

How long does Medicare CHOW take?

Medicare provider enrollment changes (CHOW or new enrollment) typically take 90-150 days through PECOS. Plan to file at LOI signing or earlier. Two structures: (1) full new enrollment, which creates a billing gap, or (2) CHOW with assumption of existing provider number, which preserves continuity but requires CMS approval. Most consolidators have CHOW expertise; the seller’s job is to support the workstream and not delay close.

What about commercial payor contract transfer?

Commercial payors (UnitedHealthcare, Anthem, Aetna, Cigna, Humana, regional Blues) typically have change-of-control or assignment clauses requiring consent or re-credentialing. Some terminate on change of ownership; others transfer with notice; others require the new entity to re-apply. Plan to map every payor contract during diligence and start transfer or re-credentialing 90-120 days before close.

What does physician retention typically look like?

Buyers typically require key physicians (selling owner + 1-3 top producers) to sign 3-5 year employment agreements with non-competes (typically 5-25 mile radius, 1-2 years post-departure depending on state law) before close. Compensation is usually wRVU-based or percentage-of-collections at FMV rates, plus quality bonuses not linked to DHS referrals. 15-30% of headline value may be contingent on physician retention via earnouts or retention bonuses.

Should I roll equity into the consolidator’s platform?

Often yes for large medical practice deals. PE consolidators typically offer rollover equity at 20-40% of total consideration, structured through partnership-tax-treated MSO entities for tax deferral. Rollover participates in the consolidator’s subsequent value creation. Risk: illiquidity and dependence on consolidator execution. For most multi-physician specialty practice sales, rolling 20-30% produces better long-term outcomes than 100% cash.

How is corporate practice of medicine handled?

Most US states impose corporate practice doctrines restricting non-physician ownership. Consolidators use MSO/PC structures: the MSO is owned by the consolidator and provides management services; the PC is owned by physicians and provides clinical services; an MSA (management services agreement) at FMV rates governs the relationship. Well-established structure but requires state-by-state legal review. Hospital systems are typically exempt from corporate practice in most states.

What about ASCs — sell with the practice or separately?

Depends on specialty and buyer. Some PE consolidators in procedural specialties (ortho, GI, ophtho) prefer to acquire the integrated ASC + practice. ASC-only consolidators (USPI, SCA, Surgery Partners) sometimes acquire the ASC separately. ASC ownership structures must comply with the AKS ASC safe harbor (1:1 ownership share to use ratio for at least one-third of physicians). Run the math both ways — integrated sale vs separate sale — before deciding.

What working capital should I expect to leave behind?

Buyer expects to receive normal operating working capital at close: 30-90 days of net AR (after denial reserve), inventory, and prepaid expenses, minus 30-60 days of AP and accrued expenses. On a $10M revenue specialty practice, that’s typically $500K-$1.5M of working capital. AR aging quality is critical — payor mix and denial rates affect collectibility. Negotiate the working capital target during the LOI.

What if I have malpractice claims history?

Malpractice history doesn’t typically kill deals but affects pricing, professional liability tail coverage costs, and indemnification structure. Buyers will require: full claims history disclosure, current professional liability coverage adequacy, tail coverage planning post-close (typically purchased as part of the deal, often $50-300K depending on specialty and history), and indemnification for pre-close claims. Get tail coverage quoted early in the process — it’s a deal cost, not a free pass.

How is CT Acquisitions different from a sell-side broker or M&A advisor?

We’re a buy-side partner, not a sell-side broker. Sell-side brokers represent you and charge you 8-12% of the deal (often $500K-$3M+ on a medical practice deal) plus monthly retainers, run a 9-12 month auction process, and require 12-month exclusivity. We work directly with 76+ buyers — including specialty PE consolidators, payor-owned platforms, ASC consolidators, hospital health systems, and physician-led MSO platforms — who pay us when a deal closes. You pay nothing. No retainer, no exclusivity, no contract until a buyer is at the closing table. You can walk after the discovery call with zero hooks. We move faster (90-180 days from intro to close) because we already know who the right buyer is rather than running an auction to find one.

Sources & References

All claims and figures in this analysis are sourced from the publicly available references below.

1. CMS — Stark Law Physician Self-Referral Overview
2. OIG — Anti-Kickback Statute Safe Harbor Regulations
3. CMS — PECOS Provider Enrollment
4. American Medical Association — Practice Transition Resources
5. CMS — National Health Expenditure Data
6. IRS — Form 8594 Asset Acquisition Statement
7. Optum (UnitedHealth Group) — About Optum Health
8. Tenet Healthcare — USPI Ambulatory Surgical Centers